BeOne Medicines Ltd.
BEIGF
$22.51
$6.5641.13%
OTC PK
| 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | |
|---|---|---|---|---|---|
| Revenue | 52.33% | 56.84% | 61.44% | 55.81% | 68.47% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 52.33% | 56.84% | 61.44% | 55.81% | 68.47% |
| Cost of Revenue | 31.37% | 164.87% | 184.76% | 216.41% | 307.31% |
| Gross Profit | 61.28% | 37.31% | 38.89% | -21.96% | -5.02% |
| SG&A Expenses | 22.92% | 20.74% | 26.66% | 24.35% | 18.29% |
| Depreciation & Amortization | -- | -- | -- | -- | -150.37% |
| Other Operating Expenses | -95.09% | -95.09% | -95.09% | 207.62% | -- |
| Total Operating Expenses | 21.72% | 20.61% | 24.52% | 23.90% | 14.87% |
| Operating Income | 86.28% | 70.85% | 50.58% | 29.94% | 45.89% |
| Income Before Tax | 82.55% | 60.24% | 32.20% | 12.65% | 73.03% |
| Income Tax Expenses | 122.97% | 144.64% | 106.10% | -3.02% | 13.09% |
| Earnings from Continuing Operations | 61.52% | 46.61% | 23.43% | 12.11% | 70.75% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 61.52% | 46.61% | 23.43% | 12.11% | 70.75% |
| EBIT | 86.28% | 70.85% | 50.58% | 29.94% | 45.89% |
| EBITDA | 101.02% | 80.42% | 57.06% | 33.19% | 49.27% |
| EPS Basic | 61.67% | 47.22% | 24.03% | 12.47% | 70.73% |
| Normalized Basic EPS | 91.37% | 74.54% | 53.68% | -27.86% | 51.80% |
| EPS Diluted | 60.46% | 47.38% | 23.05% | 12.18% | 70.35% |
| Normalized Diluted EPS | 90.81% | 74.46% | 53.68% | -27.86% | 51.80% |
| Average Basic Shares Outstanding | 1.96% | 1.11% | 0.50% | 0.06% | 0.53% |
| Average Diluted Shares Outstanding | 3.99% | 2.13% | 0.50% | 0.06% | 0.53% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -1.42% | -0.75% | -0.22% | -0.06% | -- |